| Title: |
Benefit and risk associated with interleukin-6 receptor inhibitor administration during severe COVID-19: a retrospective multicentric study |
| Authors: |
Lefèvre, Charlène; Funck-Brentano, Théo; Cachanado, Marine; Plocque, Alexia; Youinou, Maëlle; Fels, Audrey; Pène, Frédéric; Savale, Laurent; Montani, David; Voisin, Olivier; Bintein, Flore; Wildenberg, Lucille; Philippe, Axel; Legriel, Stéphane; Roche, Nicolas; Burgel, Pierre-Régis; Tran, Marc; Noël, Nicolas; Baillard, Christophe; Duranteau, Jacques; Chatellier, Gilles; Philippart, Francois |
| Contributors: |
Groupe Hospitalier Paris Saint-Joseph (hpsj); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Institut Cochin (IC UM3 (UMR 8104 / U1016)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité); Hôpital Cochin AP-HP; Hôpital Marie-Lannelongue; Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre; Hypertension pulmonaire : physiopathologie et innovation thérapeutique (HPPIT); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Université de Versailles Saint-Quentin-en-Yvelines (UVSQ); Centre Hospitalier de Versailles André Mignot (CHV); Centre de recherche en épidémiologie et santé des populations (CESP); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse; AP-HP. Université Paris Saclay-AP-HP. Université Paris Saclay-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Université Sorbonne Paris Cité (USPC); Université Paris 13 (UP13); Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)); École Pratique des Hautes Études (EPHE); Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité); Centre Marie Curie; Commissariat à l'énergie atomique et aux énergies alternatives (CEA); Institut de Biologie Intégrative de la Cellule (I2BC); Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS); Groupe Hospitalier Paris Saint‑Joseph |
| Source: |
ISSN: 2045-2322. |
| Publisher Information: |
CCSD; Nature Publishing Group |
| Publication Year: |
2026 |
| Collection: |
Université de Versailles Saint-Quentin-en-Yvelines: HAL-UVSQ |
| Subject Terms: |
Incidence (geometry); Retrospective cohort study; Tocilizumab; Complication; Observational study; Critical illness; [SDV]Life Sciences [q-bio] |
| Description: |
International audience ; During severe and critical COVID-19, therapeutic options remain scarce. Among interventions, the use of interleukin-6 receptor inhibitor (IL-6Ri) is especially controversial due to persistent uncertainty about their efficacy and safety. To compare the occurrence of secondary infections, digestive and hematological complication function of the administration of IL-6Ri we conducted a multicentric retrospective French observational study. All severe or critical COVID-19 requiring hospital admission were included. Among 2587 patients requiring hospital admission, 1603 had a severe COVID-19 and 984 a critical one requiring ICU admission. 224 received at least one dose of tocilizumab or sarilumab. Incidence of secondary infection was 29.5% in the IL-6Ri group vs. 19.5% without IL-6Ri (p = 0.0004) in the whole population. This result remained consistent after adjustment, without multiple imputation (MI) and after MI (adjusted OR: 1.47 [1.25; 1.72]; p < 0.0001)). Incidence of hematological or digestive complication were similar between groups. Mortality of patients admitted in ward was higher in the IL-6Ri group (18.7% vs 10.5%, p = 0.0155). No difference in 28 days, ICU, hospital of 90 days mortality was noticed among ICU patients.Clinical trial registration: This study was registred on ClinicalTrial.gov: NCT05017441. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/41571778; PUBMED: 41571778; PUBMEDCENTRAL: PMC12901058 |
| DOI: |
10.1038/s41598-026-36864-w |
| Availability: |
https://hal.science/hal-05502919; https://hal.science/hal-05502919v1/document; https://hal.science/hal-05502919v1/file/s41598-026-36864-w.pdf; https://doi.org/10.1038/s41598-026-36864-w |
| Rights: |
https://creativecommons.org/licenses/by-nc-nd/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.9BF6E51F |
| Database: |
BASE |